Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib plus FOLFIRI ± bevacizumab vs placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer
2014-002866-65Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metastatic colorectal adenocarcinoma (mCRC) comparing Veliparib + FOLFIRI ± bevacizumab with Placebo + FOLFIRI ± bevacizumab (2 arms). Primary endpoint: Progression-free survival. Started Oct 2014; status: completed.
02
Drugs
veliparib
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2014-002866-65.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002866-65.